PHAT (Phathom Pharmaceuticals) Insider Ownership: 5.52 % (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHAT Phathom Pharmaceuticals Inc PHAT
38 GF Score
Price $9.25
GF Value $24.98
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Phathom Pharmaceuticals Insider Ownership?

Phathom Pharmaceuticals PHAT +0.11% 38 Insider Ownership is 5.52 % as of Aug. 19, 2026. GuruFocus rates PHAT with a GF Score™ of 38/100 and a GF Value™ of $24.98 (Possible Value Trap). The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Phathom Pharmaceuticals's insider ownership is 5.52%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Phathom Pharmaceuticals's Institutional Ownership is 86.90%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Phathom Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 95.02%.

Phathom Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Phathom Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phathom Pharmaceuticals Insider Ownership Chart

Phathom Pharmaceuticals Historical Data

The historical data trend for Phathom Pharmaceuticals can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 5.32 5.23 5.29 5.48 5.48 5.55 5.56 5.61 5.61 5.52
PHAT
38GF Score
Phathom Pharmaceuticals Inc PHAT
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Phathom Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 5.52 % mean?
Phathom Pharmaceuticals (PHAT) has a Insider Ownership of 5.52 % as of Aug. 19, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Phathom Pharmaceuticals and its competitors.
Is Phathom Pharmaceuticals' Insider Ownership too high?
Phathom Pharmaceuticals' current Insider Ownership is 5.52 %. Overall, Phathom Pharmaceuticals has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Phathom Pharmaceuticals' Insider Ownership compare to GERN and KURA?
Phathom Pharmaceuticals' Insider Ownership of 5.52 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Phathom Pharmaceuticals and its competitors. Phathom Pharmaceuticals's current Insider Ownership is 5.52 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phathom Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Phathom Pharmaceuticals (PHAT) is currently considered Possible Value Trap. The stock's GF Value™ is $24.98, compared to a current price of $9.25 — trading 63% below its estimated fair value. The current Insider Ownership is 5.52 %. Phathom Pharmaceuticals' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Phathom Pharmaceuticals (PHAT), the current Insider Ownership is 5.52 % as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Phathom Pharmaceuticals (PHAT) Overvalued in 2026?

Based on GuruFocus' analysis, Phathom Pharmaceuticals stock appears to be undervalued. The current stock price of $9.25 is trading 63% below its estimated GF Value™ of $24.98. GuruFocus considers Phathom Pharmaceuticals to be Possible Value Trap.

Key valuation signals for PHAT:

  • Insider Ownership: 5.52 %
  • GF Value™: $24.98 vs. price of $9.25 (63% below fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the PHAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Phathom Pharmaceuticals Business Description

Address 100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
38GF Score

Get the complete analysis for PHAT

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.25
Price
$24.98
GF Value